ESPERITE : Extraordinary General Meeting of Shareholders 26 March 2020

February 13, 2020 Group News , Press Release (ENG)

ESPERITE N.V. convenes Extraordinary General Meeting of Shareholders on 26 March 2020

Amsterdam, The Netherlands – 13 February 2020

***

PDF Downloads – EGM 26 March 2020

           Press Release :  EGM-26-March-2020-Press-Release-1.pdf

          Agenda  :              EGM-26-March-2020-Agenda-1.pdf

          Notice  :                EGM-26-March-2020-Notice-1.pdf

Explanatory Notes :   EGM-26-March-2020-Explanatory-Notes-1.pdf

Power of Attorney :    EGM-26-March-2020-Power-of-Attorney-1.pdf

read more

ESPERITE (ESP) financial results for 2016 published

May 23, 2017 Financial Reports

ESPERITE N.V. (Euronext: ESP, “Esperite” or “the Group”) has published today its Annual Report for the year ended 31 December 2016. The 2016 Annual Report is now available on the Company’s website www.esperite.com.

  • CryoSave’s EBITDA improved from € -2.5 million to € -0.7 million.
  • Genoma’s autonomous revenue increased by 80% up to a level of € 6.9 million.
  • Esperite’s consolidated revenue decreased by 4.5% to € 26.3 million.
  • Consolidated revenues were lower than expected but the gross margin is stable and gross profit increased by 2.3%.

Zutphen, the Netherlands – 23 May 2017

read more

EN – ESPERITE financial results for 2014 published, metamorphosis completed, first positive forecast growth at €36mio Revenues (+30%) for 2015

March 17, 2015 Financial Reports , Group News

ESPERITE (“Esperite N.V. (Euronext: ESP, “ESPERITE” or “the Company”) strengthens market position of Genoma with acquisitions of exclusive technologies for fully-certified groundbreaking genetic tests.

Stem cell historical CryoSave’s core business now profitable and improving.

Consolidated operations, headcount rationalization, integrated sales and marketing strategies, laboratories integration and processes automatization completed to yield enhanced performance and results.

Zutphen, The Netherlands – 17 March 2015

read more

FR – Publication des résultats financiers 2014 de ESPERITE, métamorphose terminée, première prévision de croissance positive des revenus à 36 millions € (+30%) pour 2015

March 17, 2015 Financial Reports , Group News

ESPERITE (Esperite NV, (Euronext : ESP) « Esperite » ou « la Société ») renforce le positionnement de Genoma sur le marché par des acquisitions de technologies exclusives pour la réalisation de tests génétiques révolutionnaires entièrement certifiés.

Le coeur de métier historique de CryoSave dans les cellules souches est maintenant rentable et en constante amélioration.

Opérations consolidées, effectifs rationalisés, stratégies vente et marketing alignées, laboratoires intégrés, et processus automatisés pour l’obtention de meilleures performances et résultats.

Zutphen, Hollande – 17 Mars 2015

read more